Salix submits rifaximin NDA

SLXP submitted an NDA to the FDA for its Rifaximin rifamycin antibiotic to treat travelers' diarrhea. SLXP licensed Canadian and U.S. rights to Rifaximin from Alfa Wassermann (Bologna, Italy), which m...